Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is N/A as of Tuesday, October 6, 2026.
DEBT TO EQUITY RATIO
N/A
MiniMed Group, Inc.
Market Cap
$560.00M
Debt to Equity Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$558.41M
Debt to Equity Ratio
0.02
TTM Avg
0.04
3Y Avg
0.04
5Y Avg
0.04
Market Cap
$572.76M
Debt to Equity Ratio
N/A
TTM Avg
4.68
3Y Avg
4.68
5Y Avg
4.68
Market Cap
$540.41M
Debt to Equity Ratio
0.01
TTM Avg
0.04
3Y Avg
0.03
5Y Avg
0.02
Market Cap
$539.49M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$584.01M
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.02
5Y Avg
0.02
Market Cap
$535.61M
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.05
Market Cap
$534.74M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.23
5Y Avg
0.43
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MiniMed Group, Inc. (MMEDV) | $560.00M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $558.41M | 0.02 | 0.04 | 0.04 | 0.04 |
| CorMedix Inc. (CRMD)vs › | $564.85M | 0.31 | 0.19 | 0.10 | 0.07 |
| Aquestive Therapeutics, Inc. (AQST)vs › | $572.76M | N/A | 4.68 | 4.68 | 4.68 |
| Shattuck Labs, Inc. (STTK)vs › | $540.41M | 0.01 | 0.04 | 0.03 | 0.02 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $539.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.01M | 0.01 | 0.01 | 0.02 | 0.02 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $535.61M | 0.00 | 0.01 | 0.01 | 0.05 |
| Delcath Systems, Inc. (DCTH)vs › | $534.74M | 0.02 | 0.01 | 0.23 | 0.43 |
| ProKidney Corp. (PROK)vs › | $533.70M | N/A | 0.11 | 0.09 | 0.09 |
Debt/Equity
N/A
Current Ratio
N/A
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
